ABSTRACT Platelets isolated or in conjunction with leukocytes interact with vessel walls in many experimental and human diseases. Several mediators are held responsible for platelet activation and interaction with leukocytes, among which PAF-acether (platelet-activating factor) is a prime candidate. This phospholipid mediator is released by most inflammatory cells, including neutrophils, by isolated organs such as kidney and heart, is a potent platelet and neutrophil agonist, and exerts major vasoactive properties. Its biosynthesis involves a two-step enzymatic process yielding the active molecule from the membrane alkyl-ether choline-containing phospholipids. The first step implicates a phospholipase A2 that hydrolyzes a long-chain fatty acid (which can be arachidonic acid) from membrane phospholipids, leaving the intermediate compound lyso PAF-acether, a PAF-acether precursor that is acetylated by an acetyltransferase in a second step. It can also result from deacetylation of PAF-acether by an acetylhydrolase. PAF-acether release might explain the intervention of platelets in diseases such as glomerulonephritis and allergic vasculitis, in which the involvement of neutrophils and platelets is frequently noted. The end result of these complex sets of cell-to-cell interactions is the release of most known inflammatory mediators, influencing vascular permeability, cell infiltration, and smooth muscle contraction. Nevertheless, direct evidence for the implication of these rather welldefined cellular and molecular interactions in human pathologic states remains to be obtained. Circulation 72, No. 4, 713-717, 1985.
THE INVOLVEMENT of platelets is a common feature in various human or experimental vascular diseases. Indeed, activated platelets release coagulation and growth factors, enzymes, vasoactive amines, lipid mediators, and basic proteins, all endowed with properties that can result in vessel wall injury. In thrombi, neutrophil-platelet interaction is often seen, for which several mediators are held responsible because they are released from neutrophils and are potent inducers of platelet aggregation and release. One of them, PAFacether (platelet-activating factor), is a phospholipid that is synthesized by various cell types and organs. Therefore platelets can be instrumental in physiologic and pathologic phenomena, not only via the known pathways of hemostasis and coagulation but also as a result of their interaction with, for example, stimulated leukocytes.
A phospholipid mediator of platelet activation. In 1971, it was recognized that antigen-induced degranulation of immunoglobulin E (IgE)-sensitized basophils provoked the release in the extracellular medium of a soluble mediator, which was named platelet-activating factor (PAF). ' We subsequently demonstrated its presVol. 72, No. 4, October 1985 ence in human leukocytes and its ability to activate human platelets. Later, its physicochemical characteristics, including its phospholipid nature and the backbone of its molecular structure, were discovered, and we thereby proposed the recognition of a new class of phospholipid mediator.2 Finally, its structure was elucidated and its full synthesis achieved.3 PAF (1-0-alkyl-2-0-acetyl-sn-glyceryl-3-phosphorylcholine) is now termed "PAF-acether" to emphasize the structural features necessary for biological activity (figure 1).
Synthetic PAF-acether with Cl8 or C,6 chains at position 1 have an equipotent activity in inducing platelet aggregation and desensitization or granule enzyme release from neutrophils. By contrast, some structural features are mandatory for PAF-acether activity, such as an ether-linkage at position 1, the presence and the steric position of the short 2-acyl chain, and the presence of the choline head group.4 7 8-1 1 These data are in favor of a specific platelet receptor for PAF-acether. Indeed, recent studies show PAF-acether-specific platelet binding sites.
PAF-acether aggregates rabbit and human platelets at a concentration of 1 x 10 -9M to 10 -"M. Circulating basophils are a source for PAF-acether in the rabbit' but probably not in man.'2' "3 Release of PAFacether in the presence of the ionophore A 23187 or phagocytotic particles was observed from murine mac- Thus practically all known mechanisms of neutrophil activation can in turn bring platelets into the inflammatory site.
Another example of leukocyte-platelet interaction can be found in the onset of bronchoconstriction in the guinea pig, baboon, and man. Alveolar macrophages release PAF-acether when stimulated by a variety of agents such as zymosan particles, bacteria, immune complexes, and, in hyperimmunized animals, the specific antigen.'6 PAF-acether injected either intravenously or administered intratracheally is capable of inducing a potent bronchoconstriction that appears to be temporally related to a decrease in the number of blood platelets and neutrophils and to cell deposition in lung capillaries. These observations have been made in the guinea pig, the rabbit, the baboon, and man. Therefore mediators released from alveolar macrophages upon antigenic or nonantigenic (phagocytosis) stimulation induce platelet and neutrophil aggregation within the lung vessels. This process triggers bronchoconstriction via unknown pathways. Recently, ultrastructural evidence for the presence of aggregated platelets in the extravascular space, close to the lung smooth muscle, has been obtained after intravenous administration of PAF-acether to guinea pigs. This cascade of events, successively implicating lung macrophages, platelets, capillaries, and bronchi, offers an alternative explanation for unexplained bronchospasm in human pathologic states.
Direct vascular effects of PAF-acether. When PAFacether was administered intradermally to the rat or to humans it induced edema and in the latter case hyperalgesia.3639 This effect appears to be independent of platelets and neutrophil activation. "9 Recently, a dual response -early and late -was reported in human skin. 36 Intravenous injection of PAF-acether in rabbits, guinea pigs, baboons, and rats triggered hypotension. The phospholipid seems to be the same molecule as the antihypertensive polar renomedullary lipid described 25 years ago.4`In dogs PAF-acether induces an acute circulatory collapse.4' In all species the hypotensive effect is independent of platelet aggregation, this being particularly clear in the rat.
The only vascular response in vitro to PAF-acether stimulation that has been observed is in the rat portal vein preparation.42 There is no effect on isolated vascular muscle preparations.43 However, vessels respond to PAF-acether when present in an intact organ such as the heart. Injection of PAF-acether in isolated guinea pig heart Langendorff preparations triggers dramatic impairment in the mechanical performance of the heart and decrease in flow rate. These data would suggest an effect on the coronary circulation in the perfused organ. 4 Conclusion. Activation of platelets and neutrophils in the vascular bed is a common feature in vascular diseases. Because PAF-acether is formed by and acts on platelets and neutrophils, it may represent one of the critical links in cell-to-cell interactions, thus providing the cellular and molecular basis for potent amplifying injurious mechanisms. It also appears to have direct effect on the vasculature. However, only the development of new drugs capable of interacting specifically with the biosynthetic pathways or sites of action of the various potential mediators so far described will bring about the elucidation of their precise role in various pathologic situations.
